Vaxcyte, Inc. (PCVX)

Vaxcyte Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-766.63	-463.93	-402.27	-223.49	-100.08
Depreciation & Amortization	24.86	15.85	10.17	9.45	3.46
Loss (Gain) From Sale of Assets	-	-	-	-	0.1
Loss (Gain) From Sale of Investments	-14.43	-38.7	-34.78	-0.95	1.41
Stock-Based Compensation	138.85	84.82	48.76	23.65	10.73
Other Operating Activities	-34.77	4.23	-	8	-
Change in Accounts Payable	19.91	34.58	11.23	2.9	-12.47
Change in Other Net Operating Assets	-23.36	-89.48	70.1	9.84	-24.54
Operating Cash Flow	-655.58	-452.63	-296.79	-170.6	-121.39
Capital Expenditures	-56.97	-119.16	-67.88	-5.84	-6.56
Sale of Property, Plant & Equipment	-	-	-	-	0.03
Investment in Securities	494.33	-1,887	-705.43	80.43	-205.78
Investing Cash Flow	437.35	-2,006	-773.31	74.59	-212.31
Issuance of Common Stock	13.01	2,463	643.69	862.41	17.8
Repurchase of Common Stock	-10.99	-14.29	-3.88	-0.86	-
Financing Cash Flow	2.01	2,449	639.81	861.55	17.8
Foreign Exchange Rate Adjustments	2.44	0.43	-6.69	0.14	-0.44
Net Cash Flow	-213.77	-9.36	-436.97	765.67	-316.34
Free Cash Flow	-712.55	-571.79	-364.67	-176.44	-127.95
Free Cash Flow Per Share	-5.24	-4.69	-3.75	-2.72	-2.46
Cash Interest Paid	-	-	-	-	0.01
Levered Free Cash Flow	-430.85	-403.44	-202.41	-107.53	-88.16
Unlevered Free Cash Flow	-430.85	-403.44	-202.41	-107.52	-88.16
Change in Working Capital	-3.45	-54.9	81.32	12.74	-37.01

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q